• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Pharmaceutical Companies / GlaxoSmithKline / Gardasil Research Targets Girls from Vulnerable Communities

Gardasil Research Targets Girls from Vulnerable Communities

January 21, 2011 By Norma 9 Comments

By:  N B Sarojini and Anjali Shenoi

12 September 2010

During July and August 2009, the Andhra Pradesh and Gujarat governments, in association with the Indian Council of Medical Research (ICMR) and the Program for Appropriate Technology in Health (PATH), launched what they described as a ‘demonstration project’ for vaccination against cer­vical cancer.

Vaccines against the Human Papillomavirus (HPV) were administered to 13,791 girls in Khammam district in Andhra Pradesh, and to 9,637 girls in Vadodara district in Gujarat. The girls were between the ages of 10 and 14.

In Andhra Pradesh, the vaccine administered was Gardasil, manufactured by Merck Sharpe & Dohme (India) Pharmaceuticals Private Lim­ited (MSD), the Indian subsidiary of US-based pharmaceutical company Merck & Co. Inc.

In Gujarat, Cervarix, manufactured by GlaxoSmithKline Biologicals (GSK) of Rixensart, Bel­gium, was administered. Both vaccines were approved for marketing in India in 2008.

As part of a four-nation initiative against cervical cancer beginning in 2006, PATH has launched ‘demonstration projects’ for the HPV vaccination in Peru, Uganda, Vietnam and India, using a grant of $27.8 million from the Bill and Melinda Gates Foundation.

Women’s groups, health networks, human rights groups and child rights groups in India have been voicing concerns about the safety, efficacy and public health value of the two HPV vaccines since they were first announced.

Many joint memoranda enumerating these concerns have been submitted to the Union Minister for Health and Family Welfare, demanding an immediate halt to the ‘demonstration projects’.

On April 22, 2010, the Ministry of Health and Family Welfare (MOHFW) finally conceded that the HPV vacci­nation project was in fact a “post-licensure operational research study.”

Further investigation confirmed it as a Phase IV, post-marketing clinical trial. On April 29, the ICMR admitted that their ethical guidelines had been flouted in the course of this trial.

The trial has been temporarily suspended by the government, and a committee has been formed to conduct an inquiry. According to V. M. Katoch, ICMR Director-General:

“This is not a phase-3 clinical trial but a post-licensure observational study as the vaccine —Gardasil by MSD Pharmaceutica l— is approved for use in India. ICMR just evaluated the study’s protocol and meth­odology. The state has to monitor ethical compliance but following the objection we have asked Andhra to suspend the program till a review is done.”

This paper reflects observations made by a fact-finding team of women’s rights and health activists from Sama, Jan Swasthya Abhiyan and Anthra, who visited the Bhadrachalam project site in Andhra Pradesh.

Their investigation revealed the so-called ‘demonstration project’ to be a calculated, multi-level violation of all existing protocol on clinical trials, as well as a glaring breach of child rights.

Read the entire article here.

Related

Filed Under: GlaxoSmithKline, HPV, India, Merck & Co. Tagged With: cervarix, clinical trials, demonstration project, GlaxoSmithKline, HPV, protocol, vaccination

Trackbacks

  1. HPV Vaccine Trials In India: Is Merck Above The Law? | Natural Wellness Review says:
    July 8, 2014 at 12:29 am

    […] Court Case via an affidavit added as an addendum to the brief previously prepared regarding the ’demonstration projects’ conducted by a U.S NGO PATH in India beginning in 2009. The deaths of subjects during the […]

    Reply
  2. HPV Vaccine Trials in India: Is Merck above the law? - PRN.fm - PRN.fm says:
    July 8, 2014 at 1:54 pm

    […] Court Case via an affidavit added as an addendum to the brief previously prepared regarding the ’demonstration projects’ conducted by a U.S NGO PATH in India beginning in 2009. The deaths of subjects during the […]

    Reply
  3. Supreme Court in India to Rule on Merck Fraud Regarding HPV Vaccine Deaths | Health Impact News says:
    July 8, 2014 at 4:05 pm

    […] Court Case via an affidavit added as an addendum to the brief previously prepared regarding the ’demonstration projects’ conducted by a U.S NGO PATH in India beginning in 2009. The deaths of subjects during the […]

    Reply
  4. Ask Your Government » Blog Archive » Will India be First Country to Revoke Marketing Licenses for HPV Vaccines? says:
    August 19, 2014 at 2:49 pm

    […] https://sanevax.org/gardasil-research-targets-girls-from-vulnerable-communities/ […]

    Reply
  5. winbango » Blog Archive » Will India be First Country to Revoke Marketing Licenses for HPV Vaccines? says:
    August 19, 2014 at 4:11 pm

    […] https://sanevax.org/gardasil-research-targets-girls-from-vulnerable-communities/ […]

    Reply
  6. Will India be First Country to Revoke Marketing Licenses for HPV Vaccines? | Living For Longer says:
    August 20, 2014 at 12:00 am

    […] https://sanevax.org/gardasil-research-targets-girls-from-vulnerable-communities/ […]

    Reply
  7. India: Supreme Court HPV Vaccine Controversy Continues - Natural Wellness Review says:
    August 20, 2014 at 7:45 am

    […] https://sanevax.org/gardasil-research-targets-girls-from-vulnerable-communities/ […]

    Reply
  8. Will India be First Country to Revoke Marketing Licenses for HPV Vaccines? | Vaccine Impact says:
    November 5, 2014 at 11:04 pm

    […] https://sanevax.org/gardasil-research-targets-girls-from-vulnerable-communities/ […]

    Reply
  9. Supreme Court in India to Rule on Merck Fraud Regarding HPV Vaccine Deaths | Vaccine Impact says:
    November 20, 2014 at 5:29 pm

    […] Court Case via an affidavit added as an addendum to the brief previously prepared regarding the ’demonstration projects’ conducted by a U.S NGO PATH in India beginning in 2009. The deaths of subjects during the […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

My Gardasil Experience

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

New HPV Vaccine Documentary: Sacrificial Virgins by Joan Shenton

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in